FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362594669> ?p ?o ?g. }

• W4362594669 endingPage "710" @default.
• W4362594669 startingPage "710" @default.
• W4362594669 abstract "Abstract Within the tumor microenvironment (TME), TREGS have been associated with worse prognosis and/or resistance to checkpoint inhibitor (CPI) therapy in various cancer diseases, making these cells a promising target for the development of new immunotherapies. Here, we present recent preclinical development data about ALD2510, a next-gen low-fucose IL-2/TCONV-sparing anti-CD25 antibody designed for the selective depletion of CD25high TREGS and the boost of host anti-tumor immunity. Ultra-humanization of parental anti-CD25 antibody was achieved through phage display and, in parallel, all putative liability sequences were replaced for maximizing developability while minimizing off-target and immunogenicity risks. ALD2510 sequences were re-formatted and used for further CHO cell line development, using the GlymaxX™ technology which boosts Fc effector functions. Early tox ALD2510 material was produced following 10L fed-batch USP/DSP and analytical characterization, including a 6-month early stability study. Preliminary safety and pharmacokinetic/pharmacodynamic (PKPD) profile of ALD2510 were then determined through a non-GLP MTD/DRF study in cynomolgus monkey. ALD2510 demonstrated excellent potency (TREG depletion, ADCC, ADCP), manufacturability and stability together with very low immunogenicity potential. CHO productivity reached ~4g/L in 10L fed-batch bioreactor and characterization revealed excellent purity and activity in line with its low fucose content, together with very low levels of process- or cell-related impurities. This material showed a good behavior during the 6-month stability study and was therefore administered in cynomolgus monkeys during a non-GLP exploratory MTD/DRF study. Increasing doses of ALD2510 (from 0.3 to 100mg/kg) were given to four animals during MTD and same animals received three additional doses at 100mg/kg during DRF. Very good tolerability and safety were reported in animals. ALD2510 half-life and exposure were found consistent with that of humanized IgG1 in cynomolgus. Strong TREG depletion was monitored in the blood in all animals with, importantly, no drop was observed in CD4+ or CD8+ T-cells, confirming ALD2510 capacity to selectively target TREGS while sparing TCONV. Overall, ALD2510 demonstrated excellent potency, manufacturability and stability during the 1st phase of preclinical development. Very good tolerability and safety profile together with satisfying PKPD data were reported during exploratory MTD/DRF study in cynomolgus monkeys. Noteworthy, strong TREG depletion was confirmed while CD4+ or CD8+ T-cells were not impacted, confirming ALD2510 selectivity for TREGS while sparing TCONV. This makes ALD2510 a promising candidate for the treatment of solid tumors, in particular those where the presence of TREGS in the TME is associated with worse prognosis and/or resistance to CPI. Citation Format: Jemila Houacine, Riad Abes, Anne Marie-Cardine, Aude Le Roy, Bettina Serbin, Lucie Robert, Jérôme Giustiniani, Anne-Sophie Chrétien, Stéphane Fattori, Laurent Gorvel, Armand Bensussan, Daniel Olive, Arnaud Foussat. Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 710." @default.
• W4362594669 created "2023-04-06" @default.
• W4362594669 creator A5012827149 @default.
• W4362594669 creator A5025537277 @default.
• W4362594669 creator A5029679351 @default.
• W4362594669 creator A5030300591 @default.
• W4362594669 creator A5039848175 @default.
• W4362594669 creator A5040446667 @default.
• W4362594669 creator A5044484762 @default.
• W4362594669 creator A5061305607 @default.
• W4362594669 creator A5061551018 @default.
• W4362594669 creator A5068252024 @default.
• W4362594669 creator A5079113367 @default.
• W4362594669 creator A5082206616 @default.
• W4362594669 creator A5086020675 @default.
• W4362594669 date "2023-04-04" @default.
• W4362594669 modified "2023-09-26" @default.
• W4362594669 title "Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors" @default.
• W4362594669 doi "https://doi.org/10.1158/1538-7445.am2023-710" @default.
• W4362594669 hasPublicationYear "2023" @default.
• W4362594669 type Work @default.
• W4362594669 citedByCount "0" @default.
• W4362594669 crossrefType "journal-article" @default.
• W4362594669 hasAuthorship W4362594669A5012827149 @default.
• W4362594669 hasAuthorship W4362594669A5025537277 @default.
• W4362594669 hasAuthorship W4362594669A5029679351 @default.
• W4362594669 hasAuthorship W4362594669A5030300591 @default.
• W4362594669 hasAuthorship W4362594669A5039848175 @default.
• W4362594669 hasAuthorship W4362594669A5040446667 @default.
• W4362594669 hasAuthorship W4362594669A5044484762 @default.
• W4362594669 hasAuthorship W4362594669A5061305607 @default.
• W4362594669 hasAuthorship W4362594669A5061551018 @default.
• W4362594669 hasAuthorship W4362594669A5068252024 @default.
• W4362594669 hasAuthorship W4362594669A5079113367 @default.
• W4362594669 hasAuthorship W4362594669A5082206616 @default.
• W4362594669 hasAuthorship W4362594669A5086020675 @default.
• W4362594669 hasConcept C159654299 @default.
• W4362594669 hasConcept C203014093 @default.
• W4362594669 hasConcept C2776107976 @default.
• W4362594669 hasConcept C2780868878 @default.
• W4362594669 hasConcept C502942594 @default.
• W4362594669 hasConcept C71924100 @default.
• W4362594669 hasConcept C8891405 @default.
• W4362594669 hasConcept C98274493 @default.
• W4362594669 hasConceptScore W4362594669C159654299 @default.
• W4362594669 hasConceptScore W4362594669C203014093 @default.
• W4362594669 hasConceptScore W4362594669C2776107976 @default.
• W4362594669 hasConceptScore W4362594669C2780868878 @default.
• W4362594669 hasConceptScore W4362594669C502942594 @default.
• W4362594669 hasConceptScore W4362594669C71924100 @default.
• W4362594669 hasConceptScore W4362594669C8891405 @default.
• W4362594669 hasConceptScore W4362594669C98274493 @default.
• W4362594669 hasIssue "7_Supplement" @default.
• W4362594669 hasLocation W43625946691 @default.
• W4362594669 hasOpenAccess W4362594669 @default.
• W4362594669 hasPrimaryLocation W43625946691 @default.
• W4362594669 hasRelatedWork W1572283981 @default.
• W4362594669 hasRelatedWork W1572342804 @default.
• W4362594669 hasRelatedWork W2010057931 @default.
• W4362594669 hasRelatedWork W2030908446 @default.
• W4362594669 hasRelatedWork W2397255149 @default.
• W4362594669 hasRelatedWork W2411114470 @default.
• W4362594669 hasRelatedWork W2888060141 @default.
• W4362594669 hasRelatedWork W3045746510 @default.
• W4362594669 hasRelatedWork W3048051248 @default.
• W4362594669 hasRelatedWork W4200563690 @default.
• W4362594669 hasVolume "83" @default.
• W4362594669 isParatext "false" @default.
• W4362594669 isRetracted "false" @default.
• W4362594669 workType "article" @default.